INRLF: AI 评分 57/100 — AI 分析 (4月 2026)

Valneva SE is a specialty vaccine company focused on developing and commercializing vaccines for infectious diseases with unmet needs. The company's portfolio includes vaccines for Japanese encephalitis, cholera, and chikungunya, as well as vaccine candidates for Lyme disease, Zika virus, and other infections.

Key Facts: AI Score: 57/100 Sector: Healthcare

公司概况

概要：

Valneva SE is a specialty vaccine company focused on developing and commercializing prophylactic vaccines against infectious diseases with unmet needs, including Japanese encephalitis and chikungunya. With a global presence and a diverse pipeline of vaccine candidates, Valneva aims to address significant public health challenges and expand its market reach in the biotechnology sector.

INRLF是做什么的？

Valneva SE, founded in 1998 and headquartered in Saint-Herblain, France, is a specialty vaccine company dedicated to developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's mission is to leverage its expertise in vaccine development to address global health challenges and improve the lives of people worldwide. Valneva's commercialized product portfolio includes IXIARO, a vaccine against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholerae; and IXCHIQ/VLA1553, a single-dose vaccine for chikungunya. In addition to its commercial products, Valneva has a robust pipeline of vaccine candidates targeting diseases such as Lyme disease (VLA15), shigellosis (S4V2), Zika virus (VLA1601), human metapneumovirus (VLA1554), Clostridium difficile infection (VLA84), and Epstein-Barr virus (VLA2112). Valneva distributes its vaccines across the United States, Canada, Germany, Austria, the Nordics, the United Kingdom, France, the rest of Europe, and other international markets.

INRLF的投资论点是什么？

Valneva SE presents a notable market position within the biotechnology sector, driven by its established vaccine portfolio and promising pipeline of vaccine candidates. The company's existing commercialized vaccines, including IXIARO and DUKORAL, generate revenue and provide a foundation for future growth. The recent approval of IXCHIQ/VLA1553 for chikungunya represents a significant milestone and a potential revenue stream. Valneva's Lyme disease vaccine candidate, VLA15, is a key value driver, addressing a substantial unmet need in a growing market. The company's negative P/E ratio of -7.22 reflects its investment in R&D and clinical trials, which could yield substantial returns upon successful product launches. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from established pharmaceutical companies.

INRLF在哪个行业运营？

Valneva operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The global vaccine market is projected to reach billions of dollars by 2026, driven by increasing awareness of infectious diseases and government initiatives to promote vaccination. Valneva competes with established pharmaceutical companies and other biotechnology firms in the development and commercialization of vaccines. The company's focus on specialty vaccines for unmet needs differentiates it from competitors and positions it for growth in niche markets.

Biotechnology

Healthcare

INRLF有哪些增长机遇？

Expansion of IXCHIQ/VLA1553 for Chikungunya: Valneva's IXCHIQ vaccine, targeting the chikungunya virus, represents a significant growth opportunity. With a market size estimated to reach hundreds of millions of dollars, the vaccine addresses a critical unmet need, especially in regions where the virus is endemic. The single-dose nature of the vaccine offers a competitive advantage, simplifying administration and improving patient compliance. Successful commercialization and distribution of IXCHIQ could drive substantial revenue growth for Valneva.
Advancement of Lyme Disease Vaccine Candidate (VLA15): Valneva's VLA15 vaccine candidate against Lyme disease is a key growth driver, targeting a market with increasing prevalence and limited treatment options. The vaccine has the potential to generate significant revenue upon approval, addressing a substantial unmet need. Positive clinical trial results and regulatory approvals would be major catalysts for Valneva's growth in the coming years.
Development of Vaccine Candidates for Emerging Infectious Diseases: Valneva's pipeline includes vaccine candidates targeting emerging infectious diseases such as Zika virus, human metapneumovirus, Clostridium difficile, and Epstein-Barr virus. These programs represent long-term growth opportunities, positioning the company to address future public health threats. Successful development and commercialization of these vaccines could drive substantial revenue growth and enhance Valneva's reputation as an innovator in the vaccine space.
Geographic Expansion into New Markets: Valneva has the opportunity to expand its geographic presence into new markets, particularly in Asia and Latin America, where the prevalence of infectious diseases is high. By establishing partnerships and distribution networks in these regions, Valneva can increase its market reach and drive revenue growth. This expansion strategy aligns with the company's mission to address global health challenges and improve access to vaccines worldwide.
Strategic Partnerships and Collaborations: Valneva can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its vaccine candidates. Collaborating with other pharmaceutical companies, research institutions, and government agencies can provide access to funding, expertise, and resources, enhancing Valneva's capabilities and reducing its financial risk. These partnerships can also facilitate the expansion of Valneva's product portfolio and market reach.

Market capitalization of $0.88 billion reflects investor valuation of Valneva's current and future potential.
Gross margin of 45.4% indicates efficient vaccine production and pricing strategies.
Negative profit margin of -56.8% reflects ongoing investments in research and development for future growth.
Beta of 1.27 suggests higher volatility compared to the overall market, typical for biotechnology companies.
Valneva's diverse vaccine pipeline targets multiple infectious diseases, reducing reliance on a single product.

INRLF提供哪些产品和服务？

Develops and commercializes prophylactic vaccines for infectious diseases.
Offers IXIARO, a vaccine against Japanese encephalitis.
Provides DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera.
Markets IXCHIQ/VLA1553, a single-dose vaccine for chikungunya.
Develops VLA15, a vaccine candidate against Lyme disease.
Creates vaccine candidates for Zika virus, human metapneumovirus, and other infectious diseases.
Sells its products in the United States, Canada, Europe, and internationally.

INRLF如何赚钱？

Develops and manufactures vaccines for infectious diseases.
Generates revenue through the sale of commercialized vaccines.
Out-licenses vaccine technologies and forms strategic partnerships.
Receives funding through government grants and research collaborations.

Travelers visiting regions where Japanese encephalitis, cholera, or chikungunya are prevalent.
Military personnel deployed to areas with high risk of infectious diseases.
Individuals living in or traveling to areas endemic for Lyme disease.
Government agencies and public health organizations.

Specialized expertise in vaccine development and manufacturing.
Proprietary vaccine technologies and intellectual property.
Established distribution networks and partnerships.
Regulatory approvals and market exclusivity for commercialized vaccines.

什么因素可能推动INRLF股价上涨？

Upcoming: Clinical trial results for VLA15 (Lyme disease vaccine candidate) expected in late 2026.
Ongoing: Commercialization and distribution of IXCHIQ/VLA1553 for chikungunya.
Ongoing: Expansion of existing vaccine sales in key geographic markets.
Upcoming: Regulatory approvals for new vaccine candidates in the pipeline.
Ongoing: Strategic partnerships and collaborations to accelerate vaccine development.

INRLF的主要风险是什么？

Potential: Clinical trial failures and regulatory setbacks.
Potential: Competition from established pharmaceutical companies.
Potential: Changes in government regulations and reimbursement policies.
Ongoing: Negative profit margin due to high R&D expenses.
Potential: Product liability claims and litigation.

INRLF的核心优势是什么？

Diverse portfolio of commercialized vaccines and vaccine candidates.
Specialized expertise in vaccine development and manufacturing.
Established distribution networks in key markets.
Proprietary vaccine technologies and intellectual property.

INRLF的劣势是什么？

Negative profit margin due to high R&D expenses.
Reliance on regulatory approvals for new vaccine launches.
Competition from established pharmaceutical companies.
Limited financial resources compared to larger competitors.

INRLF有哪些机遇？

Expansion into new geographic markets.
Development of vaccine candidates for emerging infectious diseases.
Strategic partnerships and collaborations.
Increasing demand for vaccines due to global health concerns.

INRLF面临哪些威胁？

Clinical trial failures and regulatory setbacks.
Competition from biosimilars and generic vaccines.
Changes in government regulations and reimbursement policies.
Economic downturns and reduced healthcare spending.

INRLF的竞争对手是谁？

American CryoStem Corporation — Focuses on regenerative medicine rather than vaccines. — (AVCTF)
Biopharma Marchesini S.p.A. — Italian pharmaceutical company with a different product portfolio. — (BPMUF)
Eltek Ltd. — Specializes in electronics, not vaccines. — (ELEAF)
Gensight Biologics S.A. — Focuses on gene therapy for retinal diseases. — (GSGTF)
Idorsia Pharmaceuticals Ltd — Focuses on drug discovery and development, not vaccines. — (IDRSF)

Key Metrics

MoonshotScore: 57/100

Company Profile

Headquarters: Saint-Herblain, France
Employees: 713

AI Insight

AI analysis pending for INRLF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Valneva SE do?

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. The company's product portfolio includes vaccines for Japanese encephalitis (IXIARO), cholera (DUKORAL), and chikungunya (IXCHIQ/VLA1553). Valneva also has a pipeline of vaccine candidates targeting diseases such as Lyme disease, Zika virus, human metapneumovirus, Clostridium difficile, and Epstein-Barr virus. The company sells its products in the United States, Canada, Europe, and internationally, focusing on markets where these infectious diseases pose a significant public health threat.

What do analysts say about INRLF stock?

AI analysis is pending for INRLF. Generally, biotechnology stocks are evaluated based on their pipeline progress, clinical trial results, and potential market size for their products. Investors should monitor analyst ratings and price targets, but also conduct their own due diligence to assess the company's prospects and risks. Key valuation metrics include revenue growth, R&D spending, and potential earnings from future product launches. The stock's volatility should also be considered, as biotechnology stocks can be sensitive to news and regulatory developments.

What are the main risks for INRLF?

Valneva faces several risks inherent in the biotechnology industry. Clinical trial failures and regulatory setbacks are significant concerns, as delays or rejections can impact the company's pipeline and future revenue. Competition from established pharmaceutical companies with greater resources and market presence poses a challenge. Changes in government regulations and reimbursement policies can also affect the profitability of Valneva's products. Additionally, the company's negative profit margin due to high R&D expenses requires careful monitoring, as it relies on successful product launches to achieve profitability.